Literature DB >> 29486917

Systematic review of the clinical utility and validity of the Sendai and Fukuoka Consensus Guidelines for the management of intraductal papillary mucinous neoplasms of the pancreas.

Nandhini Srinivasan1, Jin-Yao Teo2, Yung-Ka Chin3, Tiffany Hennedige4, Damien M Tan3, Albert S Low5, Choon Hua Thng4, Brian K P Goh6.   

Abstract

BACKGROUND: This systematic review was performed to assess the clinical utility of the Sendai Consensus Guidelines (SCG) and Fukuoka Consensus Guidelines (FCG) for intraductal papillary mucinous neoplasm (IPMN).
METHODS: A computerized search of PubMed was performed to identify all the studies which evaluated the SCG and FCG in surgically resected, histologically confirmed IPMNs.
RESULTS: Ten studies evaluating the FCG, 8 evaluating the SCG and 4 evaluating both guidelines were included. In 14 studies evaluating the FCG, out of a total of 2498 neoplasms, 849 were malignant and 1649 were benign neoplasms. Pooled analysis showed that 751 of 1801 (42%) FCG+ve neoplasms were malignant and 599 neoplasms of 697 (86%) FCG-ve neoplasms were benign. PPV of the high risk and worrisome risk groups were 465/986 (47%) and 239/520 (46%) respectively. In 12 studies evaluating the SCG, 1234 neoplasms were analyzed of which 388 (31%) were malignant and 846 (69%) were benign. Pooled analysis demonstrated that 265 of 802 (33%) SCG+ve neoplasms were malignant and 238 of 266 SCG-ve (90%) neoplasms were benign.
CONCLUSION: The FCG had a higher positive predictive value (PPV) compared to the SCG. However, the negative predictive value (NPV) of the FCG was slightly lower than that of the SCG. Malignant and even invasive IPMN may be missed according to both guidelines.
Copyright © 2018 International Hepato-Pancreato-Biliary Association Inc. Published by Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2018        PMID: 29486917     DOI: 10.1016/j.hpb.2018.01.009

Source DB:  PubMed          Journal:  HPB (Oxford)        ISSN: 1365-182X            Impact factor:   3.647


  4 in total

1.  Comparison of imaging modalities for measuring the diameter of intraductal papillary mucinous neoplasms of the pancreas.

Authors:  Tri Huynh; Karla Ali; Shraddha Vyas; Kaleena Dezsi; Destiny Strickland; Toni Basinski; Dung-Tsa Chen; Kun Jiang; Barbara Centeno; Mokenge Malafa; Jason B Klapman; Pamela J Hodul; Daniel Jeong; Jennifer B Permuth
Journal:  Pancreatology       Date:  2020-02-21       Impact factor: 3.996

2.  Intraductal Papillary Mucinous Neoplasms: Have IAP Consensus Guidelines Changed our Approach?: Results from a Multi-institutional Study.

Authors:  Alessandra Pulvirenti; Georgios A Margonis; Vicente Morales-Oyarvide; Caitlin A McIntyre; Sharon A Lawrence; Debra A Goldman; Mithat Gonen; Matthew J Weiss; Cristina R Ferrone; Jin He; Murray F Brennan; John L Cameron; Keith D Lillemoe; T Peter Kingham; Vinod Balachandran; Motaz Qadan; Michael I D'Angelica; William R Jarnagin; Christopher L Wolfgang; Carlos Fernández-Del Castillo; Peter J Allen
Journal:  Ann Surg       Date:  2021-12-01       Impact factor: 13.787

Review 3.  Pancreatic intraductal papillary mucinous neoplasms: Current diagnosis and management.

Authors:  Beata Jabłońska; Paweł Szmigiel; Sławomir Mrowiec
Journal:  World J Gastrointest Oncol       Date:  2021-12-15

Review 4.  The Role of Positron Emission Tomography in Clinical Management of Intraductal Papillary Mucinous Neoplasms of the Pancreas.

Authors:  Simone Serafini; Cosimo Sperti; Alessandra Rosalba Brazzale; Diego Cecchin; Pietro Zucchetta; Elisa Sefora Pierobon; Alberto Ponzoni; Michele Valmasoni; Lucia Moletta
Journal:  Cancers (Basel)       Date:  2020-03-27       Impact factor: 6.639

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.